Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q44304480

about

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes Long-acting beta2-agonists for chronic obstructive pulmonary disease Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Inhaled corticosteroids for stable chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease Inhaled corticosteroids for stable chronic obstructive pulmonary disease Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease Positioning new pharmacotherapies for COPD Chronic bronchitis and chronic obstructive pulmonary disease Clinical issues of mucus accumulation in COPD Efficacy and safety of inhaler steroids in COPD patients: Systematic review and meta-analysis of randomized placebo-controlled trials Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Prevention of COPD exacerbations: medications and other controversies Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease COPD exacerbations. 4: Prevention Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update Inhaled Corticosteroids Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia.Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

P2860

Q22305858-B9C8FAA6-CE70-4E34-873E-2E99A00AAE50 Q22306079-C155952C-EC22-41FE-9119-C74340F860BB Q24197467-2018E3B1-C48F-467E-8D0A-C801A840ADB0 Q24197853-17D68903-7462-4591-B83E-F806577BE547 Q24197989-6E70F127-717E-40F6-A8BB-5CF7B752DCDD Q24199130-D43700B6-E109-44FE-AAB8-2D3616DBA14E Q24200446-95363A64-DF6D-4769-80FE-3E3FFF28B003 Q24202092-825BC1CE-AD04-4F2E-A6CF-1619A4C815A8 Q24202510-5AC45C4E-CEEB-4DED-864E-833DA887899A Q24234164-D1B522E0-3AED-4506-8DBD-CCA5A87E4C65 Q24236037-5EB37FAD-1E85-4998-B50F-F3164AEFD973 Q24243515-98827FF6-88BC-49DF-91C1-7FC703BD4B73 Q24243564-AD1FA241-5D76-4E71-A1AA-288589302ACB Q24243613-496CD5E0-1E3B-4CA2-8015-7D69EEA937DF Q24245141-6C5B4DC3-31CF-497E-8D90-5CFCF22A3933 Q24245481-02071128-0E82-4526-8949-D2C180A029D5 Q24658537-713BEB4E-9D23-4A11-BA5E-26955768922E Q26744161-BE68F273-CD50-4F4E-9703-991CCFF95C90 Q26745663-2E680AC7-82D2-4D1C-B59F-8A2C6F4B3E93 Q26798659-AFC5517E-1DDA-423F-ACD4-5DE7C66B1633 Q26991702-C04CEDFA-035C-4AFE-B3E4-0F2F118031A7 Q26992257-D838A2B1-22A7-48B6-99AB-A1844169FAD6 Q27025647-406F782F-076A-495A-8E78-E44092EA4C3F Q27348844-D081FB95-8AAE-471C-AEA6-378C0E27FC81 Q28068078-96AE4B56-0B31-4814-B70C-C3D723B1C362 Q28069762-D8F9C495-B7B6-48B7-A73A-E1E93A889F3E Q28070274-327FA275-44F5-434B-889C-CF30C1F282B1 Q28085193-AAAF1098-F9C7-4D84-A746-59EBE43BBD3A Q28391808-1170A12A-9B9A-4E3E-BE81-583DC69B3E48 Q28596774-823FC9AD-D8DE-4837-B32B-3D21BCE3F367 Q28761895-60A4DDE1-F8C3-4074-87D4-8808BB47C9AD Q30480789-8B5DE701-A58E-4585-9BD7-2C28578A5396 Q33591899-92FF7462-0E4D-4EDC-A3B4-6AC81B018415 Q33664193-45322AF0-70ED-41D1-BD68-01C890949361 Q33709357-8DF0B3DA-6A3B-4C03-BCC9-C7F1EB4A928D Q33711672-67A92842-7EE4-4BBE-A42C-C6BBEC2C249C Q33719253-23D2B25B-87E5-4AA2-88B7-0C6EF4094E8E Q33733634-DFF3EE59-6AB8-4AEA-85E7-2E46C8D9E4C5 Q33932911-1D59E5B4-3611-4B82-B49B-3B69FDA5704C Q33966009-5667EA88-28D9-440D-BC2B-E8FB3F1BC2F1

P2860

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q44304480

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@en

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@nl

type

label

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@en

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@nl

prefLabel

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@en

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@nl

P1433

Q44304480-9FC0E930-DA34-4169-BC8F-B9FED8CBE990

P1476

Q44304480-DFE7E659-CE7C-43F5-B207-244F08FB74CB

P2093

Q44304480-1FA26658-06BC-4877-9308-08E52D5E65EB

Q44304480-62669671-E8D7-46A1-971E-66B5EBDA24BC

Q44304480-6AF4C862-4B91-464E-A109-B8FCB6DCB53F

Q44304480-9CADAE75-53F7-4175-A2E6-91081ACE8015

Q44304480-A5354C60-C4B4-425B-BBF3-74BBCFCAB42A

Q44304480-C73BB40E-35F0-4B80-9A0C-0ED21861C4BF

Q44304480-DA9AAC83-724F-417F-A3C4-A40BA8534591

Q44304480-F9E5C945-8856-44EB-B3C9-CAEA91A9CFB1

P304

Q44304480-2EF8C1EB-7C4A-4AB5-819B-759CA957F679

P31

Q44304480-952A2A39-C077-4CB6-9266-2416582CE2F8

P356

Q44304480-D4873C75-3C35-4E60-92A5-AE8D69C16882

P433

Q44304480-B16E1E7C-1367-4190-ADBD-CD76463C67C2

P478

Q44304480-902A7287-30A8-4C59-AA3B-1C197C717073

P577

Q44304480-89D481AB-D3FA-4934-8118-F1A86AC7AE73

P5875

Q44304480-C183A3DB-ADDF-464D-B2EA-2F4EE09EEBA0

P698

Q44304480-359B65BF-DCD4-406B-87F4-4B7633B0D57F

P921

Q44304480-B69C624A-D487-44EB-A1DF-B0931CCB9AB8

P356

09031936.03.00031402

P1433

European Respiratory Journal

P1476

Efficacy and safety of budeson ...... obstructive pulmonary disease.

@en

P2093

A Cukier

http://www.w3.org/2001/XMLSchema#string

A Ramirez

http://www.w3.org/2001/XMLSchema#string

G Menga

http://www.w3.org/2001/XMLSchema#string

H Olsson

http://www.w3.org/2001/XMLSchema#string

R Sansores

http://www.w3.org/2001/XMLSchema#string

S Nahabedian

http://www.w3.org/2001/XMLSchema#string

S Peterson

http://www.w3.org/2001/XMLSchema#string

W Szafranski

http://www.w3.org/2001/XMLSchema#string

P304

74-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.03.00031402

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10915448

http://www.w3.org/2001/XMLSchema#string

P698

12570112

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease